X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DIVIS LABORATORIES PLETHICO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -1.1 34.4 - View Chart
P/BV x 0.0 6.7 0.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PLETHICO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-18
PLETHICO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3951,142 34.6%   
Low Rs31533 5.9%   
Sales per share (Unadj.) Rs604.4146.6 412.3%  
Earnings per share (Unadj.) Rs32.533.0 98.3%  
Cash flow per share (Unadj.) Rs51.338.4 133.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs473.6222.8 212.5%  
Shares outstanding (eoy) m34.08265.47 12.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.45.7 6.2%   
Avg P/E ratio x6.625.3 25.9%  
P/CF ratio (eoy) x4.221.8 19.0%  
Price / Book Value ratio x0.53.8 12.0%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m7,262222,318 3.3%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m1,5964,561 35.0%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m20,59838,915 52.9%  
Other income Rs m3861,134 34.1%   
Total revenues Rs m20,98440,049 52.4%   
Gross profit Rs m2,81812,617 22.3%  
Depreciation Rs m6421,425 45.1%   
Interest Rs m1,59313 11,978.9%   
Profit before tax Rs m96912,313 7.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1383,543 -3.9%   
Profit after tax Rs m1,1078,770 12.6%  
Gross profit margin %13.732.4 42.2%  
Effective tax rate %-14.328.8 -49.7%   
Net profit margin %5.422.5 23.8%  
BALANCE SHEET DATA
Current assets Rs m18,87745,351 41.6%   
Current liabilities Rs m11,8966,507 182.8%   
Net working cap to sales %33.999.8 34.0%  
Current ratio x1.67.0 22.8%  
Inventory Days Days36127 28.4%  
Debtors Days Days19895 207.9%  
Net fixed assets Rs m9,86121,160 46.6%   
Share capital Rs m341531 64.2%   
"Free" reserves Rs m12,33158,625 21.0%   
Net worth Rs m16,13959,156 27.3%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14667,832 48.9%  
Interest coverage x1.6926.8 0.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.6 108.3%   
Return on assets %8.112.9 62.9%  
Return on equity %6.914.8 46.3%  
Return on capital %12.320.8 59.0%  
Exports to sales %21.40-   
Imports to sales %15.221.8 69.8%   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,1368,485 37.0%   
Fx inflow Rs m4,40232,359 13.6%   
Fx outflow Rs m3,1849,042 35.2%   
Net fx Rs m1,21923,317 5.2%   
CASH FLOW
From Operations Rs m2,4377,759 31.4%  
From Investments Rs m-6,265-4,783 131.0%  
From Financial Activity Rs m2,490-3,142 -79.3%  
Net Cashflow Rs m-1,337-166 805.5%  

Share Holding

Indian Promoters % 82.7 52.0 159.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.8 36.4%  
FIIs % 5.5 19.0 28.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.2 43.6%  
Shareholders   10,665 31,796 33.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS